Back

Cell-Cell Fusion in NSCLC Confers a Fitness Benefit Under Drug Selection

Shultes, P. V.; Tadele, D. S.; Durmaz, A.; Weaver, D. T.; Barker-Clarke, R.; Dinh, M. N.; Liu, S.; Alemu, E. A.; Rayner, S.; Scott, J. G.

2024-12-02 cancer biology
10.1101/2024.12.02.626399 bioRxiv
Show abstract

Cell-cell fusion has been implicated in various physiological and pathological processes, including cancer progression. This study investigated the role of cell-cell fusion in non-small cell lung cancer (NSCLC), focusing on its contribution to chemoresistance and tumor evolution. By co-culturing drug-sensitive and drug-resistant NSCLC cell lines, we observed spontaneous cell-cell fusion events, particularly under gefitinib selection. These fused cells exhibited enhanced fitness and a higher degree of chemoresistance compared to parental lines across a panel of 12 chemotherapeutic agents. Further analysis, including fluorescence imaging and cell cycle analysis, confirmed nuclear fusion and increased DNA content in the fused cells. Bulk RNA sequencing revealed genomic heterogeneity in fused cells, including enrichment of gene sets associated with cell cycle progression and epithelial-mesenchymal transition, both of which are hallmarks of cancer. These findings demonstrate that cell-cell fusion can act as a novel source of chemotherapeutic resistance and further promote aggressive phenotypes in NSCLC, highlighting the potential of fusion as a therapeutic target.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.